San Antonio Breast Cancer Symposium (SABCS) 2020

08 December 2020 - 12 December 2020

Breast cancer survivors less likely to get pregnant, but babies often healthy if they do

Pearl Toh, 20210114150000

While breast cancer survivors of childbearing age are less likely to get pregnant than the general population, most of them who do become pregnant deliver healthy babies without detrimental outcomes on their long-term survival, according to a large meta-analysis presented at the SABCS 2020 Congress.

Physicians may underestimate symptoms in breast cancer patients undergoing radiotherapy

Roshini Claire Anthony, 20210107180001

Physicians may often underestimate symptoms of pain, oedema, fatigue, and pruritus in patients undergoing radiotherapy for breast cancer, according to a study presented at SABCS 2020.

Omitting radiotherapy: An option after breast-conserving surgery in older patients?

Pearl Toh, 20201229141000

Omitting radiotherapy after breast-conserving surgery in older patients with hormone receptor (HR)-positive breast cancer who were also receiving appropriate systemic therapy did not impact overall survival (OS) at 10 years, even though the rate of local recurrence was higher than those who had radiotherapy, according to the PRIME* II study presented at SABCS 2020.

Mindfulness meditation cuts depressive symptoms in young breast cancer survivors

Yoga reduces depressive symptoms in young breast cancer survivors

Pearl Toh, 20201220150000

Behavioural interventions are effective in mitigating depressive symptoms in young survivors of breast cancer, according to a study presented at SABCS 2020. In particular, mindfulness meditation also improves other outcomes related to well-being such as fatigue and sleep disturbance.

Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!

FDA-approved drug ivermectin kills SARS-CoV-2 in vitro

Stephen Padilla, 08 Apr 2020

An antiparasitic drug approved by the Food and Drug Administration (FDA) has been found to be effective in stopping the growth of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in a laboratory experiment, according to a collaborative study.

Omecamtiv mecarbil: New player in HF treatment?

Audrey Abella, 18 Dec 2020

Omecamtiv mecarbil (OM), an investigational selective cardiac myosin activator, may reduce the risk of heart failure (HF)-related events or cardiovascular (CV) deaths in patients with chronic HFrEF*, according to the late-breaking GALACTIC-HF** trial presented at AHA 2020.

Antihistamine/decongestant combo tablet trumps nasal spray in rapid relief of rhinitis

Pearl Toh, 17 Dec 2020

A single dose of loratadine/pseudoephedrine combination tablet provides over twice as much nasal relief within an hour compared with fluticasone nasal spray in patients with allergic rhinitis, according to a head-to-head comparison study presented at ACAAI 2020 Meeting.